| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Geraghty James A serves as a Director at FULC and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 6 buys and 0 sells. Those positions are worth an estimated $2.3M at current prices.
The biggest single holding is VYGR (~$1.5M) as Director. Net of sales, the recent Form 4 record there shows accumulation of 6,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2024 | PVLA Palvella Therapeutics, Inc. | Director | Buy | 1 | $1.00 | $1.00 | New | +3.3% | +137.2% | |
| Jun 28, 2021 | FULC Fulcrum Therapeutics, Inc. | Director | Buy | 10,000 | $9.16 | $91,600.00 | +12.4% | +202.6% | -46.2% | |
| Sep 10, 2018 | VYGR Voyager Therapeutics, Inc. | Director | Buy | 3,000 | $19.39 | $58,170.00 | +4.1% | - | - | |
| Aug 17, 2018 | VYGR Voyager Therapeutics, Inc. | Director | Buy | 3,000 | $18.31 | $54,930.00 | +4.3% | - | - | |
| May 15, 2018 | PVLA Palvella Therapeutics, Inc. | Director | Buy | 10,000 | $5.75 | $57,500.00 | +100.0% | - | - | |
| Aug 17, 2017 | PVLA Palvella Therapeutics, Inc. | Director | Buy | 10,000 | $4.82 | $48,200.00 | New | - | - |